Pemetrexed-13C5 (sodium salt hydrate)
目录号 : GC47933
A neuropeptide with diverse biological activities
Sample solution is provided at 25 µL, 10mM.
Pemetrexed-13C5 is intended for use as an internal standard for the quantification of pemetrexed by GC- or LC-MS. Pemetrexed is an antifolate with anticancer activity.1,2,3 It is an inhibitor of folate-dependent enzymes involved in purine synthesis, including thymidylate synthase and dihydrofolate reductase (Kis = 109 and 7 nM, respectively, for the human recombinant enzymes), and the potency for thymidylate kinase is increased following polyglutamination of pemetrexed (Ki = 1.3 nM for pemetrexed-glu5).1,2 Pemetrexed is an inhibitor of other nucleotide metabolism enzymes in a polyglutamination-dependent manner, including glycinamide ribonucleotide formyltransferase, with Ki values of 9,300 and 65 nM for the non-glutaminated and polyglutaminated mouse recombinant enzyme, respectively, and aminoimidazole carboxamide ribonucleotide formyltransferase, with Ki values of 3,600 and 265 nM for the non-glutaminated and polyglutaminated human enzyme, respectively. It inhibits proliferation of CCRF-CEM cells but not 5,10-dideazatetrahydrofolate-resistant CR15 cells (IC50s = 0.254 and 200 µM, respectively).1 Pemetrexed (100 mg/kg, i.p.) reduces tumor growth in A549, H1299, and PC-9 non-small cell lung cancer cell (NSCLC) mouse xenograft models but not in models using the same cell lines overexpressing thymidylate kinase.3
1.Shih, C., Chen, V.J., Gossett, L.S., et al.LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymesCancer Res.57(6)1116-1123(1997) 2.Hanauske, A.R., Chen, V., Paoletti, P., et al.Pemetrexed disodium: A novel antifolate clinically active against multiple solid tumorsOncologist6(4)363-373(2001) 3.Takezawa, K., Okamoto, I., Okamoto, W., et al.Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancerBr. J. Cancer104(10)1594-1601(2011)
Cas No. | N/A | SDF | |
Canonical SMILES | O=C(N[13C@H]([13C]([O-])=O)[13CH2][13CH2][13C]([O-])=O)C(C=C1)=CC=C1CCC2=CNC(NC(N)=N3)=C2C3=O.[Na+].[Na+].O.O.O.O.O.O.O | ||
分子式 | C15[13C]5H19N5O6.2Na [7H2O] | 分子量 | 602.5 |
溶解度 | DMSO: slightly soluble,Water: slightly soluble | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 1.6598 mL | 8.2988 mL | 16.5975 mL |
5 mM | 0.332 mL | 1.6598 mL | 3.3195 mL |
10 mM | 0.166 mL | 0.8299 mL | 1.6598 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet